To evaluate whether phagocytosis modulation promotes antitumour immune responses against poorly immunogenic tumors, we first evaluated whether CD47 is expressed in human and mouse glioblastoma (GBM), a malignant brain tumor. This evidence concerns the gene CD47 and brain cancer.